The term myelodysplastic syndrome (MDS) identifies a heterogeneous group of clonal disorders originating from bone marrow stem cells that often progress to acute myeloid leukemia (AML). The reference treatments for MDS include the DNA methyltransferase inhibitors azacytidine and decitabine. Recently, the epidermal growth factor receptor (EGFR) inhibitor erlotinib has been shown to exert antileukemic activity in vitro and in vivo, independent of the EGFR. Thanks to this feature, erlotinib is currently being tested as an antileukemic drug in clinical trials. Here, we report that azacytidine and erlotinib mediate synergistic antineoplastic effects in several primary or secondary (post-MDS) AML cell lines. The combination of azacytidine and erlotinib blocked cell-cycle progression and induced caspase-dependent apoptosis more consistently than either of the two agents alone. These effects were not a consequence of cellular differentiation and could be discriminated from each other, as the former depended on caspases whereas the latter did not. The synergy between azacitidine and erlotinib, which involved the proteasomal degradation of the anti-apoptotic Bcl-2 family members MCL-1 and BCL2L10 and the upregulation of their pro-apoptotic counterpart PUMA, was abolished when azacytidine was replaced by decitabine but persisted when erlotinib was substituted with gefitinib, another EGFR inhibitor. Of note, the intracellular accumulation of azacytidine was exacerbated by both erlotinib and gefitinib, pointing to a pharmacokinetic mechanism of synergy. In approximately half of the cases studied, marrow and circulating blasts from MDS and AML patients, respectively, exhibited hyperadditive cytotoxic responses to the combination of azacytidine and erlotinib. These results strongly suggest that the combination of azacytidine and erlotinib may exert clinically relevant antileukemic effects.
INTRODUCTION
Myelodysplastic syndromes (MDSs) are clonal disorders originating from bone marrow stem cells that are characterized by ineffective hematopoiesis (resulting in cytopenia) and frequent progression to acute myeloid leukemia (AML). Although the molecular pathogenesis of MDS remains largely unknown, aberrant gene methylation appears to have a major role in disease progression. Until a few years ago, high-risk MDS (International Prognostic Scoring System scores 'intermediate 2' and 'high') had a very poor median survival of about 15 months. 1 Recently, the hypomethylating agents 5-azacytidine (azacytidine) and decitabine have been shown to be superior than conventional treatments in improving the overall survival of highrisk MDS patients. 2 Thus, azacytidine and decitabine have become the first-line therapy for most MDS patients, excluding rare cases that are eligible for upfront allogeneic stem-cell transplantation. However, a limited fraction of patients respond to hypomethylating agents, and such responses are often transient. Hence, efforts are ongoing for the development of antileukemic regimens that would combine hypomethylating agents with other drugs.
The small molecules erlotinib and gefitinib, which were originally developed to inhibit the kinase activity of the epidermal growth factor receptor (EGFR), exhibit in vitro and in vivo efficacy against MDS and AML, even though blasts normally fail to express EGFR. [3] [4] [5] [6] [7] Following these encouraging preclinical results and case reports, clinical trials have been launched to investigate the safety and therapeutic potential of erlotinib in MDS and AML patients. Two of these trials (including one by our group) are still underway (NCT00977548, NCT01085838), reporting antineoplastic effects in a subset of patients. 8 Of note, erlotinib has been ascribed with a wide range of therapeutically useful off-target effects, including the capacity to inhibit transmembrane transporters of the ATPbinding cassette (ABC) family 9, 10 and to promote anticancer immune responses. 11 Multiple members of the Bcl-2 protein family, which de facto controls mitochondrial membrane permeabilization during intrinsic apoptosis, 12, 13 are deregulated in a wide array of cancers, notably in hematological malignancies such as MDS and AML. This can coincide with the overexpression of anti-apoptotic proteins such as BCL-2, BCL-X L and MCL-1, as well as with the reduced (or absent) expression of pro-apoptotic family members like BIM or 1 INSERM, U848, Villejuif, France; BAX. 14, 15 Often, the MDS-to-AML progression is accompanied by decreasing ratios of pro-apoptotic versus anti-apoptotic Bcl-2 family members, resulting in enhanced survival of malignant blasts and increased resistance to various chemotherapeutic agents. Thus, targeting Bcl-2 family members or regulators of their expression may be a meaningful strategy for the treatment of MDS and AML. In line with this notion, MCL-1 has been shown to be required for the development, sustained growth and resistance to chemotherapy of AML cells. 16, 17 Along similar lines, the overexpression of BCL2L10 (a scarcely characterized antiapoptotic member of the Bcl-2 family) reportedly predicts azacytidine resistance in MDS and AML patients. 18, 19 Oncogenic kinases such as PI3K (phosphoinositide-3-kinase), AKT1 (v-akt murine thymoma viral oncogene homolog 1), mTOR (mammalian target of rapamycin), ERK (extracellular signalregulated kinase), MEK (MAPK/ERK kinase), FLT3 (fms-related tyrosine kinase 3), JAKs (Janus kinases), IKK (IkB kinase) and PIM1 are frequently deregulated in primary AML blasts, resulting in uncontrolled cell growth and increased survival. 20, 21 Major efforts have hence been made to develop antileukemic therapies based on small molecules that specifically target these signal transducers, including SGI-1776 (an inhibitor of PIM kinases), NVP-BEZ235 and AZD8055 (interrupting PI3K and mTOR signaling), sorafenib (a broad-spectrum agent that-among other targets-interferes with the kinase activity of FLT3, MEK and ERK) and ruxolitinib (a mixed JAK1/2 inhibitor). [22] [23] [24] Interestingly, several groups have demonstrated a relationship between the antineoplastic activity of these molecules and the Bcl-2 protein family. Thus, both SGI-1776 and sorafenib reportedly kill various malignant cells, including leukemic cells (irrespective of their FLT3 mutational status), concomitant with the downregulation of MCL-1 (but not of other anti-apoptotic Bcl-2 family members such as BCL-2 and BCL-X L ). 23, 25 Accordingly, inhibitors of anti-apoptotic BCL-2-like proteins such as obatoclax and ABT-737 exacerbate the apoptotic response of AML cells to sorafenib, in vitro and in vivo.
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Based on these premises, we decided to determine if and how azacytidine and decitabine can be associated with a panel of small protein kinase inhibitors that have already been approved by the Food and Drug Administration and/or European Medicines Agency for use in cancer patients. Here, we provide the first demonstration that both erlotinib and gefitinib potently enhance the apoptotic response of AML-derived cell lines and patient blasts to azacytidine (but not decitabine) by promoting the proteasomal degradation of MCL-1 and BCL2L10 and the upregulation of PUMA. Such a synergistic effect prominently stems from a pharmacokinetic mechanism involving an increased intracellular accumulation of azacytidine promoted by EGFRtargeting chemicals.
RESULTS
Synergistic cytotoxic effects of azacytidine and erlotinib on AML cells SKM1 cells, which have been established from an MDS patient developing secondary AML, 30 were exposed to increasing concentrations of azacytidine and erlotinib for up to 48 h, followed by the determination of cellular viability using a tetrazolium conversion assay. Visual inspection of combination matrices (Figures 1a and b) , as well as calculation of the combination index following Chou and Talalay's method 31 ( Figure 1c) , revealed a significant synergy between the two agents (combination index o1). Thus, the combination of intermediate doses of azacytidine and erlotinib, but not the same concentration of either of these two agents alone, induced a significant loss in cell viability. Such a synergism was confirmed with a more direct measure of cell death-associated variables, that is, by co-staining cells with the exclusion dye propidium iodide (PI, which only labels dead cells, based on plasma membrane breakdown) plus the mitochondrial transmembrane potential (Dc m )-sensitive cyanine dye 3,3 0 dihexiloxalocarbocyanine iodide (DiOC 6 (3), which incorporates into healthy mitochondria but less so into mitochondria with a reduced Dc m ). The portion of dead (PI þ ) plus dying (PI À DiOC 6 (3) low ) SMK1 cells was markedly higher in response to azacytidine plus erlotinib than upon exposure to either azacytidine or erlotinib alone (Figure 2a) . Along similar lines, azacytidine and erlotinib synergized in the killing of three additional AML cell lines, namely MOLM-13 cells (derived from a secondary AML patient), HL-60 cells (obtained from a patient with FAB (French-American-British)-M2 AML) and MV4-11 cells (established from a patient affected by FAB-M5 AML). Conversely, KG-1 cells (derived from a patient with FAB-MO AML) and Kasumi-1 cells (similar in origin to HL-60 cells) exhibited only additive, rather than synergistic, responses to the combination treatment (Figure 2b) . Thus, azacytidine plus erlotinib exert synergistic antileukemic effects against some, but not all, AML cell lines.
When azacytidine was replaced by an equivalent concentration of decitabine, the synergism with erlotinib was lost (Figures 2a  and b) . Conversely, gefitinib behaved as erlotinib in that it greatly increased the cytotoxic potential of azacytidine ( Figure 2c ). As most AML cell lines, including SKM1 cells (data not shown), do not express EGFR, these results suggest that erlotinib and gefitinib cooperate with azacytidine through an off-target mechanism. 3 The co-administration of erlotinib (or gefitinib) and azacytidine exerted synergistic cytotoxicity also on MOLM-13 cells, which carry an activating mutation in the receptor tyrosine kinase FLT3. 32 In this model, two distinct FLT3 inhibitors, that is, sunitinib and sorafenib, behaved similar to erlotinib and gefitinib in that they exacerbated the cytotoxicity of azacytidine, a response that could not be observed in SKM1 cells (which lack FLT3 mutations; Figure 2c ). Altogether, these results indicate that a selected panel of tyrosine kinase inhibitors can mediate synergistic cytotoxicity on AML cell lines when they are combined with azacytidine.
Pro-apoptotic effects of azacytidine plus erlotinib Apoptotic cell death (i) often involves the activation of a peculiar class of cysteine proteases called caspases, 33 (ii) is often preceded by the permeabilization of mitochondrial membranes, which lose their barrier function allowing for the release of cytochrome c into the cytosol, 13, 34 and (iii) always manifests with karyorrhexis, that is, nuclear fragmentation. 35 In SKM1 cells, erlotinib combined with azacytidine (but less so either of these two agents alone) promoted the proteolytic maturation of pro-caspase-3 and the consequent cleavage of the caspase-3 substrate PARP1 (Poly (ADP-ribose) polymerase 1), leading to the formation of the characteristic B89 KDa fragment, two phenomena that could be prevented by the addition of the broad-spectrum caspase inhibitor Z-Val-Ala-Asp-fluoromethylketone (Z-VAD-fmk) ( Figures  3a and b) . Moreover, the combination of azacytidine and erlotinib induced the release of cytochrome c into the cytosol (as determined by immunofluorescence microscopy with a cytochrome c-specific antibody), which could also be rescued by Z-VAD-fmk (Figures 3c and d) . Finally, azacytidine plus erlotinib (but neither of these compounds alone) induced karyorrhexis in a Z-VAD-fmk-sensitive fashion (Figures 3c and e) . Z-VAD-fmk also inhibited azacytidine plus erlotinib-induced cell death, as determined by cytofluorometry upon co-staining with DiOC 6 (3) and PI (Figures 3f and g ). These results suggest that caspase activation has a central role in cell death as induced by the combination of azacytidine and erlotinib, both as an executioner mechanism and within feedforward loops that amplify the apoptotic signal by impinging on mitochondrial membrane permeabilization. 34 Mitochondrial apoptosis is tightly regulated by pro-and antiapoptotic members of the Bcl-2 protein family.
12 SKM1 cells responding to azacytidine plus erlotinib (but to neither of these Combination regimen with antileukemic activity E Lainey et al agents alone) manifested a major reduction in the levels of the anti-apoptotic proteins MCL-1 and BCL2L10, as well as increased amounts of the pro-apoptotic BH3-only protein PUMA (Figure 3h and Supplementary Figure S1 ). Conversely, erlotinib in combination with azacytidine failed to affect the expression levels of other members of the Bcl-2 protein family, including the anti-apoptotic proteins BCL-2 and BCL-X L as well as their pro-apoptotic counterparts BAX, BID, BIM and NOXA (Figure 3h ). Of note, the proteasomal inhibitor MG-132 completely prevented the reduction in MCL-1 and BCL2L10 levels normally occurring in response to azacytidine plus erlotinib (Supplementary Figure S2) . Confirming the importance of mitochondria in the cytotoxic response of AML cells to azacytidine and erlotinib, the addition of several pharmacological BH3 mimetics, including ABT-263 and HA14-1 (which act as combined BCL-2/BCL-X L inhibitors) and obatoclax (which operates as a general BCL-2/BCL-X L /MCL-1 inhibitor), exacerbated SKM1 cell death as triggered by either erlotinib or azacytidine (Figure 3i) . Altogether, the results of these functional assays underscore the crucial contribution of the proteasome, caspases and mitochondrial membrane permeabilization to the demise of AML cells as triggered by azacytidine plus erlotinib.
DNA damage and cell-cycle alterations caused by azacytidine plus erlotinib DNA damage foci can be detected-among other techniques-by immunofluorescence microscopy upon staining with antibodies specific for histone H2AX phosphorylated on serine 139 (gH2AX) or 53BP1. The vast majority of SKM1 cells treated with erlotinib alone manifested no or low amounts of nuclear gH2AX þ or 53BP1 þ foci, whereas the DNA damage response of SKM1 cells to azacytidine alone was slightly more pronounced (Figures 4a-c ). In the presence of both azacytidine and erlotinib, however, most SKM1 cells exhibited multiple, well-discernible gH2AX þ and 53BP1 þ foci. These results were confirmed by both cytofluorometry-and immunoblottingassisted determinations, revealing a slight accumulation of the phosphorylated form of gH2AX in SKM1 cells responding to azacytidine, which was greatly enhanced in the presence of erlotinib (Figures 4d-f ). Caspase inhibition with Z-VAD-fmk did not affect H2AX Combination regimen with antileukemic activity E Lainey et al phosphorylation as induced by azacytidine plus erlotinib, in line with the notion that this event occurs independently from (and presumably upstream of) the activation of apoptosis.
The combination of azacytidine and erlotinib failed to induce differentiation in a significant proportion of SKM1 cells, as assessed by May-Grü nwald-Giemsa staining and visual inspection (Figure 5a ), as well as by the cytofluorometric quantification of CD11b levels on the cell surface (data not shown), yet led to a consistent upregulation of the cyclin-dependent kinase inhibitor p21 WAF1 but not of its functional homolog p27 KIP1 ( Figure 5b ). Azacytidine plus erlotinib, but neither of these compounds alone, caused a major increase in the fraction of SKM1 cells with an apparent hypodiploid (o2n) DNA content (Figures 5c and d) . The accumulation of such hypodiploid cells was abolished by Z-VADfmk (Figure 5d ), confirming that it reflected the caspase-dependent fragmentation of DNA normally occurring during apoptosis. 33 In the presence of Z-VAD-fmk, SKM1 cells responding to the combination of azacytidine and erlotinib appeared to accumulate at the G 0 /G 1 phase of the cell cycle, as demonstrated by cytofluorometric assessments of DNA content (Figure 5d ). This finding was corroborated by a more exhaustive cell-cycle analysis, revealing a prominent drop in the frequency of SKM1 cells that stained positively for the nucleoside analog 5-ethynyl-2 0 -deoxyuridine (which only incorporates into cells that actively replicate their genome, that is, that are in the S phase of the cell cycle) 36 upon exposure to azacytidine plus erlotinib (Figures 5e and f). Altogether, these results plead in favor of an apoptosis-independent cell-cycle arrest induced by the combination of azacytidine plus erlotinib.
The efficacy of antineoplastic agents is optimally evaluated in clonogenic assays, rather than in classical tests that measure Combination regimen with antileukemic activity E Lainey et al proliferation or apoptosis-related variables. 37, 38 When SKM1 cells exposed to azacytidine plus erlotinib were evaluated for their clonogenic potential, two distinct phenomena could be detected. First, whereas azacytidine and erlotinib alone reduced the clonogenic survival of SKM1 to limited extents, such a loss in clonogenicity was more pronounced when these agents were used in combination (Figures 6a and b) . Second, the few colonies formed by SKM1 cells upon exposure to azacytidine plus erlotinib were considerably smaller than those formed after the administration of azacytidine or erlotinib alone, even though the latter also reduced colony size per se (Figures 6a and c) . Altogether, these results confirm that, beyond synergizing in the killing of AML cells, azacytidine and erlotinib synergistically exert cytostatic effects.
Pharmacokinetic synergism between azacytidine and erlotinib Both erlotinib and gefitinib are known to inhibit transmembrane transporters of the ABC family, including the P-glycoprotein (P-gp), the multidrug resistance protein 1 (MRP1) and the breast cancer resistance protein (BCRP).
9,10 Hence, we wondered whether a pharmacokinetic effect would account for the synergistic antileukemic activity of azacytidine and erlotinib. To test this hypothesis, we measured the cellular uptake of radioactive [ 3 H]-azacytidine in control conditions as well as in the presence of erlotinib and gefitinib. Remarkably, both erlotinib and gefitinib increased by more than twofold the accumulation of [
3 H]-azacytidine in SK1 cells (Figure 7a ). Neither chemical inhibitors of P-gp (that is, verapamil), BRCP (that is, cyclosporine A) and MRP1 (that is, MK-571) used as single agent nor the multi-kinase inhibitor dasatinib exerted a similar effect. On the contrary, the simultaneous administration of verapamil, cyclosporine A and MK-571 consistently augmented the intracellular levels of Combination regimen with antileukemic activity E Lainey et al azacytidine de facto result in an accrued cytotoxic response, we treated SKM1 cells with azacytidine and erlotinib, alone or combined with verapamil, cyclosporine A and MK-571. As depicted in Figure 7c , the simultaneous inhibition of P-gp, MRP1 and BCRP failed to significantly exacerbate the cytotoxic potential of erlotinib. Along similar lines, the concomitant administration of verapamil, cyclosporine A and MK-571 was unable to augment the cytotoxic response of SKM1 cells to azacytidine plus erlotinib, yet it mimicked erlotinib in its capacity to synergize with azacytidine ( Figure 7c ). Taken together, these data demonstrate that azacytidine and erlotinib exert synergistic antileukemic effects as a result of a pharmacokinetic interaction.
Synergistic cytotoxic effects of azacytidine and erlotinib or primary AML and MDS cells To substantiate the possible translational relevance of our findings, we obtained bone marrow CD34 þ cells from MDS patients or circulating blasts from individuals with overt AML (Supplementary Table S1 ). We then cultured these cells for 48 h, either in control conditions or in the presence of azacytidine and erlotinib, alone or in combination, followed by DiOC 6 (3)/PI costaining and cytofluorometric assessments of apoptosis-related parameters. We found that the combination therapy induces 3.3-to-3.6-fold more cell death (considering the sum of dying-PI À DiOC 6 (3) low -and dead-PI þ -cells) than the administration Table S2 ). Accordingly, CD34
þ cells from 21 out of 41 patients exhibited additive cell death responses to the combination regimen (Figures 8a-d ). We were unable to establish any significant correlation between the type of response to azacytidine and erlotinib in vitro (hyperadditive versus additive or hypoadditive effect) and clinical or pathological features of the patients (including age, gender, type of disease, relapse, so on). Nonetheless, cells from primary AML patients responded better to the combination therapy than cells from MDS-bearing subjects (Po0.01, ANOVA plus unpaired Student's t-test; Figure 8e ). Altogether, these ex vivo results suggest that the combination of azacytidine and erlotinib might constitute an effective approach against MDS and AML, at least in a fraction of patients.
DISCUSSION
In this study, we report that the two mechanistically distinct antineoplastic agents, that is, the DNA methyltransferase inhibitor azacytidine and the EGFR inhibitor erlotinib, mediate synergistic cytotoxic and antiproliferative effects on leukemic cell lines as well as on primary malignant cells obtained from MDS and AML patients. Decitabine failed to exert synergistic effects when combined to erlotinib, in line with recent reports indicating that azacytidine and decitabine-at odds with long-standing convictions-operate via distinct modes of action. [39] [40] [41] Conversely, gefitinib, another EGFR inhibitor, was capable of exacerbating the antineoplastic effects of azacytidine similarly to its functional counterpart erlotinib. However, as most AML cells, including those used here, do not express the molecular target of erlotinib and gefitinib, that is, EGFR, 3 azacytidine and erlotinib appear to cooperate via EGFR-independent mechanisms.
We have previously reported that azacytidine can inhibit NF-kB signaling in human myelomonocytoid P39 cells through an offtarget effect, an activity that is shared by decitabine. 42 However, in the cellular model that we used most extensively in this work, SKM1 cells, azacytidine failed to affect the nuclear redistribution of NF-kB (not shown), suggesting that other mechanisms would account for the cytotoxic and antiproliferative effects of azacytidine plus erlotinib. Erlotinib reportedly inhibits SRC kinases 43 and mTOR. 44 However, while dasatinib completely inhibited SRC kinases in SKM1 cells (not shown), it failed to synergistically interact with azacytidine. Along similar lines, the mTOR inhibitor rapamycin was incapable of killing SKM1 cells in the presence of azacytidine (not shown), arguing against a major implication of mTOR in the antineoplastic synergism of azacytidine plus erlotinib. As both erlotinib and gefitinib inhibit ABC transporters, 9,10 we tested whether a pharmacokinetic effect would account for the synergistic antileukemic activity of azacytidine and erlotinib. Indeed, both erlotinib and gefitinib significantly incremented the cellular accumulation of azacytidine, correlating with their capacity to exacerbate azacytidine cytotoxicity. The existence of a pharmacokinetic interaction between azacytidine and erlotinib was confirmed by two additional lines of evidence. First, dasatinib neither stimulated the intracellular accumulation of azacytidine nor synergized with it in the killing of SKM1 cells. Second, the cytotoxic response of SKM1 cells to azacytidine, but not to azacytidine plus erlotinib, was exacerbated by the simultaneous administration of inhibitors of P-gp, MRP1 and BCRP, along with an accrued intracellular accumulation of the demethylating agent.
Azacytidine plus erlotinib exert clear pro-apoptotic effects, as indicated by the fact that the broad-spectrum caspase inhibitor Z-VAD-fmk can prevent both the acquisition of the apoptotic phenotype (with marked chromatinolysis, nuclear fragmentation and cellular pyknosis) and signs of irreversible cellular deterioration (such as Dc m dissipation and plasma membrane permeabilization) as induced by these agents. In the course of azacytidine plus erlotinib-induced cell death, we detected alterations in the expression levels of Bcl-2 family proteins, notably reduced levels of the anti-apoptotic proteins MCL-1 and BCL2L10 (owing to proteasomal degradation) and increased expression of their proapoptotic counterpart PUMA. In line with the hypothesis that such Figure 6 . Impact of azacytidine and erlotinib on the number and size of colonies formed by SKM1 cells. SKM1 cells were seeded in a methylcellulose-based medium containing DMSO (control condition), 0.15 mM azacytidine (AZA, A) or 2.5 mM erlotinib (ERLO, E), alone or in combination, and allowed to generate colonies for 14 days. At the end of the assay, the number and volume of colonies were quantified. Combination regimen with antileukemic activity E Lainey et al alterations might be relevant for the synergistic cytotoxicity exerted by azacytidine and erlotinib, we found that a range of pharmacological BH3 mimetics sensitize AML cell lines to either of these agents when used alone. Beyond this, it appears that azacytidine plus erlotinib can stimulate an arrest in the G 0 /G 1 phase of the cell cycle that is independent of their pro-apoptotic activity, as revealed by the fact that it could still be appreciated in the presence of Z-VAD-fmk. This was further confirmed with clonogenic assays, showing that the few cells that survive azacytidine plus erlotinib generate colonies that are much smaller in size than those generated by cells surviving either of these agents alone. Hence, the combination of azacytidine and erlotinib has a dual antileukemic action, which consists in cell death induction plus cell-cycle blockade.
It is tempting to speculate that the combination of azacytidine and erlotinib might be useful in the clinic, based on several considerations. First, both agents are relatively safe and associated with limited side effects (compared with conventional cytotoxic chemotherapy), meaning that they might be particularly useful in subjects like the elderly (who, moreover, are not eligible for allogeneic stem cell transplantation). Second, on near-to-half malignant cell samples freshly drawn from MDS and AML patients, the combination of azacytidine and erlotinib exerted hyperadditive cytotoxic effects, pointing to a promising efficacy. Third, the combination of azacytidine and erlotinib, but not either compound alone, induced the downregulation of BCL2L10. As high BCL2L10 expression levels have recently been linked to azacytidine resistance in MDS and AML patients, 18 ,19 the use of azacytidine plus erlotinib might convey a major therapeutic advantage over the administration of either compound alone. Unfortunately, we have thus far been unable to identify a biological or clinical parameter that would predict such a hyperadditive effect. It remains possible (though formal evidence is hitherto missing) that the assay that we used to characterize hyperadditive (and hence bona fide synergistic) antineoplastic effects from azacytidine plus erlotinib in vitro, on purified CD34
þ cells, might be used to select those patients who would benefit from a combinatorial treatment. This question may only be resolved by a well-designed clinical trial.
MATERIALS AND METHODS

Patient samples and CD34
þ cell selection
Patient samples were studied after obtaining informed consent according to the Declaration of Helsinki. AML and MDS were diagnosed by morphological examination of peripheral blood and bone marrow biopsies, according to the WHO 2008 and FAB classifications. Patients' characteristics are reported in Supplementary Table S1 . Mononuclear cells from the peripheral blood or bone marrow were isolated using a FicollPaque PLUS density gradient (Amersham Biosciences, Sunnyvale, CA, USA).
To obtain CD34 þ cells from mononuclear cells, a positive selection with the MiniMacs system (Miltenyi Biotec, Bergisch Gladbach, Germany) was carried out according to the manufacturer's instructions.
Chemical, cell lines and culture conditions
Unless otherwise indicated, chemicals were purchased from Sigma-Aldrich (St Louis, MO, USA), while media and supplements for cell culture from Gibco-Invitrogen (Carlsbad, CA, USA). Erlotinib hydrochloride, gefitinib, sorafenib, imatinib, and sunitinib were purchased by LC Laboratories (Woburn, MA, USA). Lapatinib ditosylate (GW-572016), dasatinib (BMS-354825), ABT-263 (navitoclax), obatoclax mesylate (GX15-070) and MG-132 were obtained by Selleck Chemicals LLC (Houston, TX, USA). 5-Azacytidine (Vidaza), decitabine (Dacogen), HA14-1, Z-VAD-fmk and verapamil hydrochloride were purchased by Ben Venue Laboratories (Bedford, OH, USA), MGI Pharma (Bloomington, MN, USA), Tocris (Ellisville, MO, USA), Bachem Bioscience (Bubendorf, Switzerland) and Calbiochem (San Diago, CA, USA), respectively. [
3 H]-azacytidine (8.9 Ci/mmol, from Moravek Biochemicals, Brea, CA, USA) was a generous gift from Celgene (San Francisco, CA, USA). All chemicals were dissolved in dimethyl sulfoxide (DMSO) and stored at À 20 1C. An appropriate volume of DMSO was invariably used to provide negative control conditions. Patient-derived CD34 þ cells were cultured (37 1C, 5% CO 2 ) in Iscove's modified Dulbecco medium supplemented with 1% L-glutamine, 100 units/ml penicillin sodium plus 100 mg/ml streptomycin sulfate, 10 ng/ml interleukin-3 (Peprotech, Neuilly-sur-Seine, France), 10 ng/ml interleukin-6 (Peprotech), 50 ng/ml thrombopoietin (Peprotech), 100 ng/ml FLT3-ligand (Miltenyi Biotec), 50 ng/ml stem cell factor (Miltenyi Biotec) and 20% BIT 9500 serum substitute (200 mg/ml transferrin, 10 mg/ml insulin, 2% bovine serum albumin; from StemCell Technologies, Grenoble, France). The SKM1 cell line was a kind gift of Patrick Auberger (INSERM U895, Nice, France), while MOLM-13, KG-1, Kasumi-1, HL-60 and MV411 cells were purchased from the DSMZ (Braunschweig, Germany). All cell lines were cultured in RPMI 1640 medium supplemented with 20% fetal calf serum. Cells in the logarithmic phase of growth seeded at a density of 2 Â 10 5 /ml were used for all experiments.
Colorimetric assays
Preliminary in vitro assessments of the antineoplastic effects of azacytidine and erlotinib (alone and in combination) were carried out by means of a colorimetric 3-(4,5-dimethyl-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4- Cytofluorometric assessment of apoptosis, cell cycle distribution and DNA synthesis Apoptosis-related parameters, cell-cycle distribution and the percentage of cells in the S phase of the cell cycle were quantified as previously reported. 36, 37, 45 For apoptosis determinations, live cells were co-stained with 20 nM DiOC 6 (3) (from Molecular Probes-Invitrogen, Eugene, CA, USA), which measures mitochondrial transmembrane potential (Dc m ), and 1 mg/ml PI, which identifies cells with ruptured plasma membrane. For the assessment of cell-cycle distribution, 5 Â 10 5 cells were collected, washed once with ice-cold phosphate-buffered saline (PBS) and permeabilized with 100 ml of 0.5% Triton x-100. Thereafter, cells were stained with 50 mg/ml PI in 0. Clonogenic assays SKM1 cells were seeded at a concentration of 10 000/dish in MethoCult H4434 classic methylcellulose-based medium (StemCell Technologies), in the presence of 0.15 mM azacytidine, 2.5 mM erlotinib, 0.15 mM azacytidine plus 2.5 mM erlotinib, or an equivalent volume of DMSO. Fourteen days later, dishes were imaged by a GBox imaging system (Syngene, Cambridge, UK) and colonies were quantified for both number and size with the GeneTool software (Syngene). Only colonies made of approximately 450 cells were retained for further analysis. þ cells isolated from patients affected by MDS (n ¼ 9), primary AML (n ¼ 21) or secondary AML (sAML, n ¼ 11) were maintained in controls conditions (DMSO) or incubated with 1 mM azacytidine (AZA, A) and 10 mM erlotinib (ERLO, E), alone or in combination, for 48 h. Thereafter, cells were subjected to cytofluorometry for the assessment of apoptosis-associated variables upon co-staining with the Dc m -sensitive fluorochrome DiOC 6 (3) and the exclusion dye PI. Immunofluorescence microscopy Slides for immunofluorescence microscopy were prepared as previously described. 48, 49 In brief, cells were allowed to adhere on polylysine-L-coated coverslips and fixed in 4% paraformaldehyde for 20 min at room temperature. Thereafter, cells were permeabilized with 0.1% SDS for 10 min, washed in PBS and stained with primary antibodies specific for gH2AX (mouse monoclonal, No. 05-636, Upstate-Millipore) 53BP1 (rabbit polyclonal, No. A300-272A; Bethyl Laboratories, Montgomery, TX, USA) or cytochrome c (mouse monoclonal, No. 556432, BD Biosciences). Revelation was performed with appropriate secondary antibodies coupled to Alexa Fluor 488 or Alexa Fluor 568 fluorochromes (Molecular Probes-Invitrogen). Nuclear counterstaining was obtained with 10 mM Hoechst 33342 (Molecular Probes-Invitrogen). At least 100 cells for each slide were examined and scored independently for the presence of H2AXg þ nuclear foci, 53BP1 þ nuclear foci or cytoplasmic cytochrome c on a Observer.Z1 microscope (Zeiss, Thornwood, NY, USA) at Â 63 magnification.
Intracellular phosphoprotein analysis
The phosphorylation of status of H2AX on Ser 139 was assessed by cytofluorometry, following standard procedures. Briefly, cells were stained with the LIVE/DEAD Fixable Dead Cell Stain Kit (Invitrogen) for 30 min at 37 1C (to exclude dead cells at analysis), fixed with 1.5% paraformaldehyde for 10 min at room temperature, washed twice with PBS and permeabilized in 1 ml ice-cold 95% methanol for 10 min. Cells were then rehydrated with 5% fetal calf serum (v/v in Hank's balanced salt solution) for 30 min at 4 1C, washed with PBS and pellets were incubated for 1 h at 4 1C in the dark with an anti-gH2AX-FITC conjugate (No. 16-202A, Upstate-Millipore). Rabbit unrelated IgGs (Santa Cruz Biotechnology, Santa Cruz, CA, USA) were used as isotype controls. Samples stained with unconjugated rabbit IgGs were washed twice with PBS and incubated for further 30 min in the dark with secondary goat anti-rabbit FITC-conjugates (Molecular Probes, Invitrogen). Fluorescence was monitored on a Gallios cytofluorometer (Beckman Coulter, Brea, CA, USA) and analysis was performed on the Kaluza software (Beckman Coulter). Changes in fluorescence were calculated as the ratio between the mean fluorescence intensity of stained samples and the mean fluorescence intensity of isotype controls. Results are expressed as percentage of phosphorylation as normalized to control (DMSO-treated) cells.
Quantification of intracellular erlotinib
Erlotinib was quantified on a Rapid Resolution Liquid Chromatography (RRLC) 1200SL system coupled to a 6410 Triple Quadripole (QQQ) mass spectrometer (both from Agilent Technologies, Santa Clara, CA, USA). To this aim, 10 6 cells were lysed in 1 ml 80% ice-cold methanol (v/v in water), vortexed for 1 min and incubated on ice for 30 min. Lysates were then centrifuged at 13 000 g for 10 min at 4 1C, supernatants were dried in a SpeedVac drier (Thermo Scientific-Pierce, Rockford, IL, USA), resuspended in 200 ml 2% methanol (v/v in water) and directly injected into the HPLC-QQQ system. RRLC was performed on 150 Â 2.1 mm, 3.5 mM Eclipse Plus columns (Agilent Technologies) with water containing 0.1% formic acid and 7.5 mM ammonium formiate in channel A and methanol in channel B, in gradient mode: t ¼ 0 min, 5% B; t ¼ 10 min, 95% B; t ¼ 12 min; 95% B; re-equilibration time ¼ 6 min. Mass spectrometry was performed in positive electrospray ionization mode at þ 4 kV on the QQQ system operating in MRM (multiple reaction monitoring)mode. MRM transitions were optimized with direct infusions of erlotinib, and two transitions were recorded. The parent ion (MH þ 394.2) at a fragmentor voltage of 180 V gave two daughter ions: one of 336.2 Da at a collision energy of 24 V and one of 278.1 Da at a collision energy of 32 V.
Quantification of intracellular [
3 H]-azacytidine SKM1 cells seeded in 96-well plates were incubated with the compounds of interest for 15 min, followed by exposure to 10 nM [ 3 H]-azacytidine for 1 h. Cells were then collected and lysed in 200 ml 1M NH 4 OH (5 min). Extracts were transferred to scintillation vials, complemented with 3 ml Ultima Gold XR liquid scintillation cocktail (Perkin Elmer, Waltham, MA, USA) and analyzed for radioactivity on a Tri-Carb 2810TR liquid scintillation analyzer (Perkin Elmer).
Assessment of cellular differentiation
Differentiation was assessed morphologically, upon May-Grü nwaldGiemsa staining. To this aim, cells were cytospun onto slides, fixed with absolute methanol for 15 min at room temperature and then sequentially stained with the May-Grü nwald and Giemsa reagents as previously described. 50 Signs of differentiation (that is, decreased cytoplasmic basophilia, decreased nucleus/cytoplasm ratio, appearance of granulation and nuclear lobulation) were then quantified in at least 100 cells for each experimental conditions on a Primo Star microscope (Zeiss) equipped with a Plan-Achromat Â 100/1.25 oil immersion objective and a AxioCam EEc 5s CCD camera (both from Zeiss).
Data treatment and statistical analyses
The impact of disease type and drug treatment on log-linearized PI þ plus PI À DiOC 6 (3) low cell percentages were evaluated by linear mixed-effects modeling, with patient id taken as the random effect. 51 Pairwise differences between samples treated with azacytidine only, erlotinib only and azacytidine plus erlotinib were derived by extracting all possible contrasts from the model built with the drug treatment factor only. Contrasts are presented in their original scale and after backtransformation to facilitate the interpretation. Unless otherwise specified, all experiments were carried out in triplicate parallel instances and independently repeated at least three times. Data were analyzed with Excel (Microsoft, Redmont, WA, USA), Prism5 (GraphPad Software, La Jolla, CA, USA) or with the free, open-source R Studio integrated development environment (http://rstudio.org/). Statistical significance was assessed by ANOVA followed by Dunnett's tests, two-tailed unpaired Student's t-tests or Bonferroni's post-hoc tests, as appropriate. P values o0.05 were considered statistically significant.
